Home Pregnancy Test Evaluation, Lay User Study

February 4, 2021 updated by: SPD Development Company Limited

Evaluation of Home Pregnancy Test by Lay Users Study

This study is a performance evaluation study to assess the performance of a home pregnancy test (HPT) in the hands of lay users by comparing their results, when used according to the Instructions for Use (IFU), to (a) the lay user confirmed pregnancy status, as determined by a CE marked product, and (b) to trained technicians testing the same urine samples.

The study will also assess the lay user's ability to correctly read results from randomised standards, in addition to leaflet comprehension and product ease of use.

Study Overview

Status

Completed

Conditions

Detailed Description

This is an observational study, designed to assess the performance of a home pregnancy test.

The study aims to recruit at total 120 volunteers, being approximately equal numbers of 'pregnant' and not-pregnant' women. Volunteers will be recruited either via direct invitation or advertisement and will attend the study site for one visit lasting 30-40 minutes

Written informed consent will be obtained from all volunteers prior to starting the study.

All volunteers will be issues a unique study number on admission to the study. All data and samples collected will be anonymised throughout the study.

Volunteers will be provided with one investigational home pregnancy test and instructions for use. They will be asked to conduct the test, following the product instructions to obtain a test result which will be recorded on the result sheet. Volunteers will be instructed the product is investigational and the results should not be relied upon to determine their pregnancy status.

Study volunteers will then be interviewed by the study technician, with regards to their understanding of the product instructions and complete an ease of use questionnaire. The comprehension interview may be recorded.

The study technician will then perform 2 further investigational home pregnancy tests on randomised urine standards and the volunteer will read the results.

Finally, the study technician will test the volunteer's urine sample with a marketed pregnancy test and record these results on the results sheet. The results of this test will be used to provide the volunteer with her pregnancy status at the end of the study.

Urine samples provided by the volunteers will be tested with the investigational HPT by an independent technician and also measured for hCG by quantitative immunoassay. Samples may also be measured for other hormones related to pregnancy and fertility.

With participant permission, the samples may be retained frozen within the SPD BioBank and used for future product evaluation or research purposes.

Study Type

Observational

Enrollment (Actual)

129

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Bedfordshire
      • Bedford, Bedfordshire, United Kingdom, MK44 3UP
        • SPD Development Company Ltd

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Female volunteers representative of home pregnancy test users.

Description

Inclusion Criteria:

  • Willing to give informed consent
  • Willing to conduct a personal home pregnancy test and reveal their pregnancy status
  • Seeking to conceive, wishing to conduct a pregnancy test or having recently found out they are pregnant

Exclusion Criteria:

  • Currently or previously employed by SPD, Abbott, Alere, Unipath, P&G or affiliates
  • Has an immediate relative currently or previously (within last 5 years) employed by SPD, Abbott, Alere, Unipath or P&G, or affiliates
  • Healthcare professionals (HCP's) with professional experience either using lateral flow-based devices or conducting near patient testing
  • If pregnant, known to be beyond the first trimester (defined as last menstrual period, LMP +13 weeks)
  • aken a hormonal preparation containing hCG in the last month, e.g. Pregnyl ®
  • Has previously taken part in this study
  • Seen the product within the past 6 months

Immediate relatives are defined as parents, children, siblings or partner/spouse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Agreement with pregnancy status
Time Frame: 3 months
The accuracy of the investigational HPT will be calculated against the confirmed pregnancy status of the sample. The corresponding 95% confidence interval will also be calculated for the measure.
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Agreement with technician results
Time Frame: 3 months
The agreement between the lay-user and technician results when both testing the same sample with the investigational HPT as per the IFU. The corresponding 95% confidence interval will also be calculated for the measure.
3 months
Comprehension of instructions for use
Time Frame: 3 months
The percentage number of correct answers in the IFU comprehension exercise
3 months
Ease of product use
Time Frame: 3 months
The cumulative Likert scores for ease of use questions on the device usability questionnaire will be calculated, using a 7 point likert scale, where 1 is equivalent to very easy and 7 is equivalent to very difficult.
3 months
Ability to read result
Time Frame: 3 months
The agreement between the lay-user read of a investigational HPT tested with a spiked standard against the expected result of the spiked standard. The corresponding 95% confidence interval will also be calculated.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sarah Johnson, SPD Development Company Ltd

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 8, 2020

Primary Completion (Actual)

November 4, 2020

Study Completion (Actual)

November 4, 2020

Study Registration Dates

First Submitted

April 21, 2020

First Submitted That Met QC Criteria

April 29, 2020

First Posted (Actual)

May 4, 2020

Study Record Updates

Last Update Posted (Actual)

February 9, 2021

Last Update Submitted That Met QC Criteria

February 4, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • PROTOCOL-1146

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy Related

3
Subscribe